Fig. 4: Accuracy of assessing Aβ and tau-PET status by region in the validation cohort demonstrates superior performance of plasma eMTBR-tau243 over %p-tau217 and %p-tau205.
From: Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
a, ROC curves for the three plasma biomarkers to assess tau-PET status in Aβ-positive individuals (n = 436). AUCs are included in the figure and asterisks represent significantly different AUCs from that of plasma eMTBR-tau243. b, AUCs (dots) and 95% CIs (black lines) for all PET status outcomes (listed on the left) shown for each plasma biomarker (color coded) in Aβ-positive individuals (n = 436). c, The same analysis presented for all participants (n = 649 for tau-PET and n = 483 for Aβ-PET). Asterisks represent significantly different (P < 0.05) AUCs from that of plasma eMTBR-tau243, assessed using the DeLong test. All tests were two sided. Specific P values can be found in Supplementary Table 6.
